Article

Cataract in patients with diabetes mellitus—incidence rates in the UK and risk factors

Received:
Revised:
Accepted:
Published online:

Abstract

Aims:

To analyze the risk of incident cataract (diagnosis or extraction) in patients with or without diabetes focusing on other comorbid conditions, antidiabetic drug use, and diabetes duration.

Methods:

The study population comprised newly diagnosed diabetes patients (≥40 years) from the UK-based Clinical Practice Research Datalink (CPRD) between 2000 and 2015, and a random sample of the general population matched for age, sex, general practice, and year of diabetes diagnosis. We assessed cataract incidence rates (IRs) and performed a nested case-control analysis in the diabetic cohort to assess potential risk factors for a cataract.

Results

There were 56,510 diabetes patients included in the study. IRs of cataract were 20.4 (95% CI 19.8–20.9) per 1000 person-years (py) in patients with diabetes and 10.8 (95% CI 10.5–11.2) per 1000 py in the general population. IRs increased considerably around the age of 80 years and with a concomitant diagnosis of macular edema. The incidence rate ratio (IRR) was highest in patients of the age group of 45–54 years. In the nested case-control study, we identified 5800 patients with cataract. Risk of cataract increased with increasing diabetes duration (adj. OR 5.14, 95% CI 4.19–6.30 diabetes for ≥10 years vs. diabetes <2 years).

Conclusions:

According to our study, diabetes is associated with an approximately two-fold increased detection rate of cataract. The risk of cataract associated with diabetes is highest at younger ages. Patients with diabetic macular edema are at an increased risk for cataract as well as patients with long-standing diabetes.

  • Subscribe to Eye for full access:

    $350

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013;1:e339–49.

  2. 2.

    Asbell PA, Dualan I, Mindel J, Brocks D, Ahmad M, Epstein S. Age-related cataract. Lancet. 2005;365:599–609.

  3. 3.

    Tan JS, Wang JJ, Younan C, Cumming RG, Rochtchina E, Mitchell P. Smoking and the long-term incidence of cataract: the Blue Mountains Eye Study. Ophthalmic Epidemiol. 2008;15:155–61.

  4. 4.

    Hollows F, Moran D. Cataract–the ultraviolet risk factor. Lancet. 1981;2:1249–50.

  5. 5.

    Urban RCJ, Cotlier E. Corticosteroid-induced cataract. Surv Ophthalmol. 1986;31:102–10.

  6. 6.

    Delcourt C, Cristol JP, Tessier F, Leger CL, Michel F, Papoz L. Risk factors for cortical, nuclear, and posterior subcapsular cataracts: the POLA study. Pathologies Oculaires Liees a l’Age. Am J Epidemiol. 2000;151:497–504.

  7. 7.

    Laitinen A, Laatikainen L, Harkanen T, Koskinen S, Reunanen A, Aromaa A. Prevalence of major eye diseases and causes of visual impairment in the adult Finnish population: a nationwide population-based survey. Acta Ophthalmol. 2010;88:463–71.

  8. 8.

    Theodoropoulou S, Theodossiadis P, Samoli E, Vergados I, Lagiou P, Tzonou A. The epidemiology of cataract: a study in Greece. Acta Ophthalmol. 2011;89:e167–73.

  9. 9.

    Li L, Wan XH, Zhao GH. Meta-analysis of the risk of cataract in type 2 diabetes. BMC Ophthalmol. 2014;14:94.

  10. 10.

    Harding JJ, Egerton M, van Heyningen R, Harding RS. Diabetes, glaucoma, sex, and cataract: analysis of combined data from two case control studies. Br J Ophthalmol. 1993;77:2–6.

  11. 11.

    Janghorbani MB, Jones RB, Allison SP. Incidence of and risk factors for cataract among diabetes clinic attenders. Ophthalmic Epidemiol. 2000;7:13–25.

  12. 12.

    Machan CM, Hrynchak PK, Irving EL. Age-related cataract is associated with type 2 diabetes and statin use. Optom Vision Sci: Off Publ Am Acad Optom. 2012;89:1165–71.

  13. 13.

    Jaycock P, Johnston RL, Taylor H, Adams M, Tole DM, Galloway P, et al. The Cataract National Dataset electronic multi-centre audit of 55,567 operations: updating benchmark standards of care in the United Kingdom and internationally. Eye. 2009;23:38–49.

  14. 14.

    Walley T, Mantgani A. The UK general practice research database. Lancet. 1997;350:1097–9.

  15. 15.

    Williams T, van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf. 2012;3:89–99.

  16. 16.

    Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, et al. Validity of the general practice research database. Pharmacotherapy. 2003;23:686–9.

  17. 17.

    Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69:4–14.

  18. 18.

    Lawrenson R, Williams T, Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med. 1999;21:299–304.

  19. 19.

    Klein BE, Klein R, Moss SE. Incidence of cataract surgery in the wisconsin epidemiologic study of diabetic retinopathy. Am J Ophthalmol. 1995;119:295–300.

  20. 20.

    Kang EM, Pinheiro SP, Hammad TA, Abou-Ali A. Evaluating the validity of clinical codes to identify cataract and glaucoma in the UK Clinical Practice Research Datalink. Pharmacoepidemiol Drug Saf. 2015;24:38–44.

Download references

Acknowledgements

We thank Dr Annette Beiderbeck (Alimera Science Ophthalmologie GmbH, Berlin, Germany), Dr John Hall (Alimera Science Ltd, Aldershot, UK) for their scientific input during the conduct of the study, and Pascal Egger (Basel Pharmacoepidemiology Unit; University of Basel, Switzerland) for his technical support and programming.

Funding

The study was supported by an unconditional grant of Alimera Science Ltd.

Author information

Affiliations

  1. Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland

    • Claudia Becker
    • , Cornelia Schneider
    •  & Christoph Meier
  2. Hospital Pharmacy, University Hospital Basel, Basel, Switzerland

    • Cornelia Schneider
    •  & Christoph Meier
  3. Creative Ceutical Ltd, London, UK

    • Samuel Aballéa
  4. University Hospitals Bristol NHS Foundation Trust, Bristol, UK

    • Clare Bailey
  5. Vision and Eye Research Unit, Postgraduate Medical Institute, Faculty of Medical Science, Anglia Ruskin University, Cambridge, UK

    • Rupert Bourne
  6. Boston Collaborative Drug Surveillance Program, Boston University School of Public Health, Lexington, MA, USA

    • Susan Jick
  7. Boston Collaborative Drug Surveillance Program, Lexington, MA, USA

    • Christoph Meier

Authors

  1. Search for Claudia Becker in:

  2. Search for Cornelia Schneider in:

  3. Search for Samuel Aballéa in:

  4. Search for Clare Bailey in:

  5. Search for Rupert Bourne in:

  6. Search for Susan Jick in:

  7. Search for Christoph Meier in:

Conflicts of interest

The authors declare that they have no competing interests.

Corresponding author

Correspondence to Christoph Meier.